Laddar...
Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer
Resistance to chemotherapy remains a critical barrier to effective cancer treatment. Although cisplatin is one of the most commonly used chemotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resistance to this drug are not fully understood. Here, we report a n...
Sparad:
| I publikationen: | Oncogene |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8274951/ https://ncbi.nlm.nih.gov/pubmed/30093630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0429-3 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|